Logo image of MACK

MERRIMACK PHARMACEUTICALS IN (MACK) Stock Fundamental Analysis

NASDAQ:MACK - Nasdaq - US5903282094 - Common Stock - Currency: USD

15.13  0 (0%)

After market: 15.16 +0.03 (+0.2%)

Fundamental Rating

4

MACK gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MACK as it has an excellent financial health rating, but there are worries on the profitability. MACK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MACK had positive earnings in the past year.
MACK had a negative operating cash flow in the past year.
MACK had negative earnings in each of the past 5 years.
MACK had a negative operating cash flow in each of the past 5 years.
MACK Yearly Net Income VS EBIT VS OCF VS FCFMACK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

1.2 Ratios

Looking at the Return On Assets, with a value of 82.05%, MACK belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
MACK has a Return On Equity of 90.44%. This is amongst the best in the industry. MACK outperforms 99.66% of its industry peers.
Industry RankSector Rank
ROA 82.05%
ROE 90.44%
ROIC N/A
ROA(3y)-10.25%
ROA(5y)-26.93%
ROE(3y)-10.57%
ROE(5y)-30.09%
ROIC(3y)N/A
ROIC(5y)N/A
MACK Yearly ROA, ROE, ROICMACK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

MACK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MACK Yearly Profit, Operating, Gross MarginsMACK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

MACK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MACK has been increased compared to 5 years ago.
There is no outstanding debt for MACK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MACK Yearly Shares OutstandingMACK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
MACK Yearly Total Debt VS Total AssetsMACK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 4.99 indicates that MACK is not in any danger for bankruptcy at the moment.
The Altman-Z score of MACK (4.99) is better than 78.56% of its industry peers.
There is no outstanding debt for MACK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.99
ROIC/WACCN/A
WACCN/A
MACK Yearly LT Debt VS Equity VS FCFMACK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M

2.3 Liquidity

MACK has a Current Ratio of 10.78. This indicates that MACK is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 10.78, MACK is doing good in the industry, outperforming 79.42% of the companies in the same industry.
A Quick Ratio of 10.78 indicates that MACK has no problem at all paying its short term obligations.
MACK has a better Quick ratio (10.78) than 79.42% of its industry peers.
Industry RankSector Rank
Current Ratio 10.78
Quick Ratio 10.78
MACK Yearly Current Assets VS Current LiabilitesMACK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 10764.04% over the past year.
EPS 1Y (TTM)10764.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69750%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MACK Yearly Revenue VS EstimatesMACK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 20M 40M 60M 80M 100M
MACK Yearly EPS VS EstimatesMACK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 0 10 -10 20 30

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 1.09, which indicates a rather cheap valuation of MACK.
MACK's Price/Earnings ratio is rather cheap when compared to the industry. MACK is cheaper than 99.14% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.68, MACK is valued rather cheaply.
Industry RankSector Rank
PE 1.09
Fwd PE N/A
MACK Price Earnings VS Forward Price EarningsMACK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MACK Per share dataMACK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 99.80%, MACK is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 108.81, MACK pays a better dividend. On top of this MACK pays more dividend than 99.83% of the companies listed in the same industry.
MACK's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
Industry RankSector Rank
Dividend Yield 99.8%

5.2 History

MACK does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MACK Yearly Dividends per shareMACK Yearly Dividends per shareYearly Dividends per share 2019 2024 5 10 15

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
MACK Yearly Income VS Free CF VS DividendMACK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

More info and screens

MERRIMACK PHARMACEUTICALS IN

NASDAQ:MACK (5/17/2024, 8:11:51 PM)

After market: 15.16 +0.03 (+0.2%)

15.13

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2024-05-13/amc
Earnings (Next)08-01 2024-08-01/amc
Inst Owners4.89%
Inst Owner Change-96.72%
Ins Owners32.31%
Ins Owner Change0%
Market Cap223.77M
Analysts45
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 99.8%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1.09
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)13.86
EY91.61%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0
BVpS14.99
TBVpS14.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 82.05%
ROE 90.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.25%
ROA(5y)-26.93%
ROE(3y)-10.57%
ROE(5y)-30.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.78
Quick Ratio 10.78
Altman-Z 4.99
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10764.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69750%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1804.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1804.62%
OCF growth 3YN/A
OCF growth 5YN/A